← Leaderboards
Thomas G Evans
Aeras
$771,067
Attributed
$771,067
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $619K · FY2012–19$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$771,067 · 2
By mechanism
R01$619,046 · 1
U19$152,021 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesCytomegalovirusRegimenVaccine CandidateT Cell ResponseReportingImmunogenicityProduct DevelopmentResponseVaccinationVertebral ColumnVectorSuccessBaseGenerationsGenesMacaca MulattaPre-ClinicalBackFibroblastsAttenuationEngineeringEnsureEpitopes
Grant awards (4)
Clinical Development of a Safety and Efficacy-Optimized 2nd Generation HCMV/HIV Vector for a Prophylactic HIV/AIDS Vaccine$2
U19 · FY2019 · AI · contact PI
Clinical Development of a Safety and Efficacy-Optimized 2nd Generation HCMV/HIV Vector for a Prophylactic HIV/AIDS Vaccine$1
U19 · FY2018 · AI · contact PI
Clinical Development of a Safety and Efficacy-Optimized 2nd Generation HCMV/HIV Vector for a Prophylactic HIV/AIDS Vaccine$152,018
U19 · FY2017 · AI · contact PI
Generation and Evaluation of Pro-Apoptotic rBCG and Viral Vectors as TB Vaccine C$619,046
R01 · FY2012 · AI · contact PI